Prommer E: Ziconotide: Can we use it in palliative care?Am J Hosp Palliat Med. 2005; 22(5): 369-374.
2.
Penn RD, Paice JA: Adverse effects associated with the intrathecal administration of ziconotide. Pain. 200085(1-2): 291-296.
3.
Staats PS, Yearwood T, Charapata SG, et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA. 2004; 291(1): 63-70.
4.
Webster LR: A double-blind, placebo-controlled study of the efficacy of intrathecal ziconotide for the treatment of severe chronic pain in adults. Pain Med. 2005; 6(2): 195-196.
5.
Prialt® US Package insert, 2004.
6.
Malmberg AB, Yaksh TL: Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain. 1995; 60(1): 83-90.
7.
Dissanayake S, Ver Donck A, Vercruysse P, et al.: No pharmacological toerance to intrathecal ziconotide observed in chronic pain patients receiving long-term (12 months) treatment. Poster presented at the International Association for the Study of Pain Conference, 2003.
8.
Characterization of long-term intrathecal Prialt use for patients with severe chronic pain following initial slow titration (AAPM Annual Meeting Abstracts). Pain Med. 2005; 6(2): 194.
9.
Yaksh TL, Hassenbusch S, Burchiel K, et al.: Inflammatory masses associated with intrathecal drug infusion: A review of preclinical evidence and human data. Pain Med. 2002; 3(4): 300-312.
